Reckitt Benckiser (LON:RB) has been given a GBX 7,000 ($93.92) price target by analysts at JPMorgan Chase in a report released on Friday, May 11th. The firm currently has a “buy” rating on the stock. JPMorgan Chase’s target price would suggest a potential upside of 17.69% from the company’s current price.
Several other analysts have also recently issued reports on RB. Liberum Capital reissued a “buy” rating and set a GBX 8,000 ($107.34) price objective on shares of Reckitt Benckiser in a research note on Monday, February 19th. Goldman Sachs set a GBX 6,910 ($92.71) price objective on shares of Reckitt Benckiser and gave the company a “neutral” rating in a research note on Thursday, January 25th. BNP Paribas reduced their target price on shares of Reckitt Benckiser from GBX 7,200 ($96.61) to GBX 6,000 ($80.50) and set a “neutral” rating on the stock in a report on Tuesday, May 8th. Credit Suisse Group reduced their target price on shares of Reckitt Benckiser from GBX 5,500 ($73.80) to GBX 5,450 ($73.12) and set a “neutral” rating on the stock in a report on Monday, April 30th. Finally, Societe Generale set a GBX 6,500 ($87.21) target price on shares of Reckitt Benckiser and gave the company a “buy” rating in a report on Thursday, March 22nd. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of GBX 7,045.22 ($94.53).
Shares of Reckitt Benckiser stock opened at GBX 5,948 ($79.81) on Friday. Reckitt Benckiser has a 1 year low of GBX 5,562 ($74.63) and a 1 year high of GBX 8,110.43 ($108.82).
In related news, insider Rakesh Kapoor sold 120,000 shares of the company’s stock in a transaction that occurred on Friday, May 4th. The shares were sold at an average price of GBX 5,576 ($74.82), for a total value of £6,691,200 ($8,977,861.26).
Reckitt Benckiser Company Profile
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.